Fluorescence Spectroscopy for Non-Invasive Diabetes Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diabetes screening methods are invasive, inconvenient, and unreliable, often leading to late detection and misclassification, with a need for a non-invasive, accurate, and high-throughput method to detect diabetes and its progression.
Innovation Solution
A non-invasive method using fluorescence spectroscopy to quantify Advanced Glycation End-Products (AGEs) in the eye, employing a confocal setup with a blue LED light source and optical bandpass filters to detect fluorescent light intensity and backscattered excitation light, normalized to account for tissue opacity and age variations, combined with machine learning algorithms for disease state prediction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If blood sampling methods (FPG, OGTT) are used for diabetes screening, then reliable glucose level measurement is achieved, but the procedure becomes invasive, inconvenient, and prone to misclassification
Solution Approach 1:
The patent replaces the mechanical invasive blood sampling system with an optical fluorescence spectroscopy system. The confocal microscope uses light excitation to detect AGEs in the ocular lens, eliminating the need for venous draws and making the screening non-invasive and convenient while maintaining diagnostic accuracy.
Solution Approach 2:
The patent introduces AGEs (Advanced Glycation End-products) in the ocular lens as an intermediary biomarker. Instead of directly measuring blood glucose, the system detects AGEs accumulation in the lens, which serves as a reliable indirect indicator of diabetes status and progression, avoiding the limitations of direct blood sampling.
2Reliability
If FPG and OGTT tests are used, then diabetes diagnosis is achieved, but the tests require fasting and can only be administered during morning appointments, reducing productivity
Solution Approach 1:
The patent performs preliminary detection of AGEs in the ocular lens, which accumulate over time and reflect long-term glycemic control. This preliminary action allows screening to be conducted at any time without fasting requirements, as the AGEs biomarker is not affected by short-term glucose fluctuations, thereby increasing screening productivity.
Solution Approach 2:
The patent utilizes the periodic accumulation nature of AGEs in the lens, which reflect chronic glycemic exposure rather than acute glucose levels. This periodic biomarker特性 allows flexible scheduling of screenings without the constraints of fasting periods or specific appointment times, enhancing healthcare system productivity.
3Loss of time
If single FPG test is used for screening, then quick diagnosis is achieved, but approximately one-half of those with diabetes are misclassified, worsening reliability
Solution Approach 1:
The patent replaces the single-point blood glucose measurement system with a fluorescence spectroscopy system that detects AGEs accumulation in the ocular lens. This substitution provides a more reliable biomarker that reflects long-term glycemic control, reducing misclassification rates while maintaining efficient screening timing.
Solution Approach 2:
The patent creates a copy of the glycemic control information stored in the ocular lens AGEs. Instead of relying on a single blood glucose snapshot, the system reads the accumulated glycemic history encoded in the lens proteins, providing a more accurate representation of true diabetes status and reducing false positives/negatives.
4Measurement precision
If OGTT is used for diagnosis, then comprehensive glucose tolerance assessment is achieved, but the test suffers from poor reproducibility and requires 2 hours after glucose load, increasing loss of time
Solution Approach 1:
The patent uses AGEs in the ocular lens as an intermediary biomarker that captures long-term glucose tolerance information without requiring acute glucose challenge. This intermediary provides comprehensive assessment of glycemic control with a single quick measurement, eliminating the need for 2-hour glucose loading and improving reproducibility.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables early and accurate detection of diabetes, reducing the need for invasive tests and improving compliance, with enhanced precision and sensitivity for high-throughput screening, capable of distinguishing between diabetes stages and complications.
Implementation Method 1
illuminate ocular tissue with an excitation light source and detect autofluorescence induced in the ocular tissue in response to the excitation light
Implementation Method 2
detecting light emitted by the tissue due to fluorescence of a chemical in the tissue responsive to the excitation light
Data Source
Figure 1~2
Figure 3A~3B
Figure 4~6
AI summary
Methods for spectroscopic analysis of biological tissues to classify an individual as diabetic or non-diabetic, or to determine the probability, progression or level of a disease or medical condition in an individual.